Ace the Case: Treating First Multiple Myeloma Relapse in the Community Setting is organized by Healio, American Academy of CME, Inc..
Release date: 02/10/2023
Expiration date: 02/10/2024
Activity Description:
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, hematologists, nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals) who manage patients with relapsed/refractory multiple myeloma.
Learning Objectives:
After participating in the activity, learners should be better able to:
- Consider the role of newly approved agents and emerging strategies in treating newly diagnosed and RRMM based upon information in clinical guidelines and expert insights
- Outline interprofessional approaches to manage patients with RRMM and recognize and mitigate toxicities associated with newly approved agents
- Describe patient and caregiver education for newly approved agents, including early recognition of toxicities and communication with health care team to mitigate the risk of developing severe complications